|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
ADmark® Early Onset Alzheimer's Evaluation
Test Code93086
CPT Codes
81405, 81406 (x2), 81479<br>Limited Access Code
Physician Attestation of Informed Consent
This germline genetic test requires physician attestation that patient consent has been received if ordering medical facility is located in AK, DE, FL, GA, IA, MA, MN, NV, NJ, NY, OR, SD or VT or test is performed in MA.
Includes
ADmark® APP DNA Sequencing/Duplication Test, ADmark® PS-1 DNA Sequencing Test, ADmark® PS-2 DNA Sequencing Test
Preferred Specimen
8 mL whole blood collected in EDTA (lavender-top) tube
Minimum Volume
6 mL
Instructions
Special Notes: Athena does not perform this test for individuals under the age of 18.
Stability restrictions: Specimen must arrive in Chantilly Sunday through Wednesday within 24 hours of collection. Athena accepts specimens for this test Monday through Thursday only.
Higher blood volumes ensure adequate DNA quantity, which varies with WBC, specimen condition, and need for confirmatory testing.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 10 days
Refrigerated: 10 days
Frozen: Unacceptable
Refrigerated: 10 days
Frozen: Unacceptable
Methodology
Next Generation Sequencing • Dosage Analysis
FDA Status
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Varies; Report available: 21-28 days
Reference Range
No sequence variation detected
Clinical Significance
Detects sequence variants in the PS-1, PS-2, and APP genes. Detects duplications in the APP gene.